User menu

Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content

Bibliographic reference Anello, Marcello ; Gilon, Patrick ; Henquin, Jean-Claude. Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content. In: British Journal of Pharmacology, Vol. 127, no. 8, p. 1883-1891 (1999)
Permanent URL http://hdl.handle.net/2078.1/13006
  1. AGUILAR-BRYAN, Physiol. Rev., 78, 227 (1998)
  2. ASHCROFT, TINS, 21, 288 (1998)
  3. BEST, Biochem. Pharmacol., 43, 2483 (1992)
  4. BORG, Acta Diabetol. Lat., 18, 65 (1980)
  5. CATTANEO, Int. J. Clin. Pharmacol. Ther. Toxicol., 28, 229 (1990)
  6. DETIMARY, J. Clin. Invest., 96, 1738 (1995)
  7. Dunne M.J., Petersen O.H., Potassium selective ion channels in insulin-secreting cells: physiology, pharmacology and their role in stimulus-secretion coupling, 10.1016/0304-4157(91)90012-l
  8. ELIASSON, J. Physiol., 503, 399 (1997)
  9. FILIPPONI, Endocrinology, 113, 1972 (1983)
  10. GEMBAL, J. Clin. Invest., 91, 871 (1993)
  11. GEMBAL, J. Clin. Invest., 89, 1288 (1992)
  12. GILON, J. Biol. Chem., 267, 20713 (1992)
  13. GOLD, Diabetes, 35, 6 (1986)
  14. GROOP, Diabetes Care, 15, 737 (1992)
  15. HELLMAN, Eur. J. Clin. Invest., 20, S10 (1990)
  16. HELLMAN, Acta Endocrinol., 105, 389 (1984)
  17. HENQUIN, Nature, 271, 271 (1978)
  18. HENQUIN, J.C. (1990). Established, unsuspected and novel pharmacological insulin secretagogues. In New Antdiabetic Drugs. Bailey, C.J., Flatt, P.R., eds. London: Smith-Gordon pp 93-106.
  19. HENQUIN, J.C. (1994). The cell biology of insulin secretion. In The Joslin's Diabetes Mellitus. 13th edn. Kahn, C.R., Weir, G.C., eds. Philadelphia: Lea & Febiger, pp 56-80.
  20. HENQUIN, Endocrinology, 139, 993 (1998)
  21. HEPTNER, Pharmacol. Res., 1, 215 (1984)
  22. HOSOKAWA, Diabetes, 46, 808 (1997)
  23. JABER, Diabetes Care, 17, 1300 (1994)
  24. JONAS, Diabetes, 47, 1266 (1998)
  25. KANE, Nature Med., 2, 1344 (1996)
  26. LEAHY, Diabetes Rev., 4, 298 (1996)
  27. MATTHEWS, Diabet. Med., 15, 297 (1998)
  28. MISLER, Diabetes, 41, 1221 (1992)
  29. PANTEN, Biochem. Pharmacol., 38, 1217 (1989)
  30. PANTEN, U. , SCHWANSTECHER, M. & SCHWANSTECHER, C. (1996). Mode of action of sulphonylureas. In Oral Antidiabetics. Kuhlmann J., Puls, W., eds. Springer Verlag: Berlin, Heidelberg, pp 129-159.
  31. PANTEN, Naunyn-Schmiedeberg's Arch. Pharmacol., 338, 459 (1988)
  32. PONTIROLI, Diabetes Metab. Rev., 10, 31 (1994)
  33. PRENTKI, Eur. J. Endocrinol., 134, 272 (1996)
  34. RABUAZZO, Endocrinology, 131, 1815 (1992)
  35. ROE, Am. J. Physiol., 266, E852 (1994)
  36. SAKO, Diabetes, 39, 1580 (1990)
  37. SARTOR, Eur. J. Clin. Pharmacol., 17, 285 (1980)
  38. SATIN, Endocrine, 4, 191 (1996)
  39. SATO, Diabetes, 41, 438 (1992)
  40. SATO, Endocrinology, 140, 2252 (1999)
  41. SATO, Diabetes, 47, 1713 (1998)
  42. Sturgess N.C., Kozlowski R.Z., Carrington C.A., Hales C.N., Ashford M.L.J., Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line, 10.1111/j.1476-5381.1988.tb16551.x
  43. UK PROSPECTIVE DIABETES STUDY GROUP. (1998). Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet, 352, 837-853.
  44. WILKE, Endokrinologie, 76, S357 (1980)
  45. Z�nkler B.J., Lenzen S., Manner K., Panten U., Trube G., Concentration-dependent effects of tolbutamide, meglitinide, glipizide, glibenclamide and diazoxide on ATP-regulated K+ currents in pancreatic B-cells, 10.1007/bf00169252